Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Combination Therapy · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Combination Therapy | COMBINATION_PRODUCT | tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination |
| Monotherapy obicetrapib | DRUG | tablet; 10mg obicetrapib |
| Monotherapy ezetimibe | DRUG | capsule; 10mg ezetimibe |
| Combination Therapy placebo | OTHER | tablet; no active ingredient |
| Obicetrapib Placebo | OTHER | tablet; no active ingredient |
| Ezetimibe Placebo | OTHER | capsule; no active ingredient |
Combination Therapy is an investigational small molecule being studied for dyslipidemias, including hypercholesterolemia, familial hypercholesterolemia, ASCVD, and high cholesterol. It combines obicetrapib and ezetimibe as a fixed dose combination, intended for use on top of maximum tolerated lipid-modifying therapies.
Combination Therapy is being developed by NewAmsterdam Pharma Company N.V., a biopharmaceutical company traded on the stock exchange under the ticker NAMS. The company is conducting clinical research on this fixed dose combination of obicetrapib and ezetimibe for cardiovascular conditions.
Combination Therapy is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug remains under investigation for the treatment of dyslipidemias.
Combination Therapy has one completed Phase 3 clinical trial, identified as NCT06005597. The study, titled 'Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies,' enrolled 407 participants with dyslipidemias and related conditions.
Combination Therapy is a fixed dose combination of obicetrapib and ezetimibe, meaning it contains both drugs in a single formulation. It is being studied as a combination therapy, distinct from each drug used alone, for the management of dyslipidemias.